Toronto, ON; July 17, 2023 – Proteocyte AI is pleased to announce the publication of its latest clinical research paper by Applied Immunohistochemistry & Molecular Morphology (AIMM). The paper strongly supports the risk assessment system used as part of STRATICYTE™, Proteocyte’s first oral cancer risk assessment product.
Entitled “Assessing Oral Epithelial Dysplasia Risk for Transformation to Cancer: Comparison Between Histologic Grading Systems Versus S100A7 Immunohistochemical Signature-based Grading”, the newly published paper is the latest milestone in Proteocyte’s continuing leadership in developing a range of technological solutions that predict a patient’s risk of developing oral cancer. In the previous quarter, the company was awarded an important patent in the United States for the first oral dysplasia prognostic test of its kind, STRATICYTE.
The paper concluded: In this study, the S100A7 IHC signature-based risk assessment (STRATICYTE) was the best and only predictor of clinical outcome [cancer]; both the [WHO] 3-tier and 2-tier systems of oral epithelial dysplasia grading failed to adequately stratify high-risk from low-risk of transformation cases, resulting in false negatives. The abstract and link to the full paper can be viewed here.
Dr. Anthony Morlandt, Chief Medical Officer at Proteocyte: “This latest publication further supports STRATICYTE’s status as a ground-breaking tool in oral cancer risk detection. The study shows that the existing standard of testing for oral cancer risk is lacking, and that the risk system inherent in our product provides a new standard that will improve risk assessment and detection.”
Proteocyte is a personalized medical diagnostics company located in MaRS Centre, Toronto, ON. Proteocyte’s product helps tackle the uncertainty surrounding oral cancer care, one of the most aggressive human cancers. The company’s oral dysplasia predictive test, STRATICYTE™, was developed from a panel of 811 protein biomarkers, leverages over 10 years of R&D, and is positioned to disrupt oral dysplasia and cancer care worldwide.